MetaVia Inc

MetaVia Inc. seeks to disrupt cardiometabolic care with cutting‑edge therapies amid financial headwinds—investors see long‑term upside despite short‑term volatility.

MetaVia Inc. raises $9.3 M in a public offering to speed its obesity drug vanoglipel and dyslipidemia program, despite a 26 % stock dip.

MetaVia Inc. develops innovative dyslipidemia therapies amid financial volatility, targeting cardiovascular disease solutions with potential growth once clinical trials succeed.

MetaVia Inc, a biopharmaceutical company, faces challenges in a volatile market, but remains committed to developing therapies for dyslipidemia and potentially offers opportunities for future growth.